Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress by jonadmin | May 22, 2023 | Uncategorized
Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates by jonadmin | Mar 28, 2023 | Uncategorized
Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction by jonadmin | Sep 29, 2022 | Uncategorized
Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer by jonadmin | May 25, 2022 | Uncategorized
Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases by jonadmin | Mar 8, 2022 | Uncategorized
Recent Comments